Titre:
  • CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
Auteur:Dhainaut, Jean-Francois; Vincent, Jean Louis; Richard, Carol; Lejeune, Philippe; Martin, Charlotte; Fierobe, L; Stephens, S; Ney, Michaëlle; Sopwith, M
Informations sur la publication:Critical care medicine, 23, 9, page (1461-1469)
Statut de publication:Publié, 1995-09
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:APACHE
Aged
Aged, 80 and over
Antibodies, Monoclonal -- immunology -- pharmacokinetics -- therapeutic use
Antibody Formation
Cytokines -- blood
Dose-Response Relationship, Drug
Female
Humans
Interleukin-1 -- biosynthesis
Interleukin-6 -- biosynthesis
Male
Middle Aged
Prospective Studies
Shock, Septic -- drug therapy -- immunology -- mortality
Survival Analysis
Tumor Necrosis Factor-alpha -- immunology -- metabolism
Note générale:Clinical Trial
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0090-3493
info:pmid/7664546